As we continue to deal with the unprecedented economic and fitness emergency caused by COVID-19, it is imperative that we take every measure imaginable to ensure the fitness of vulnerable patient populations, adding the nearly 38 million Americans with chronic kidney failure Before the crisis erupted, kidney patients faced the main barriers to accessing health care. Now, with an expanding research framework, government knowledge, and CDC warnings that appear to have a disproportionate effect on COVID-19 on kidney patients, especially minorities, policymakers want to take proactive steps to ensure that CR patients can access care safely while avoiding exposure.
The multifaceted network of kidney care providers continued to provide dialysis care to patients with end-stage renal impairment (TRI) or renal failure in this crisis, but patients with undesteed CKD still face growing threats in the safe remedy of iron deficiency anemia (ADI) – a non-unusual complication of CRA that particularly decreases the patient’s quality of life and ability to work , increases the threat of central attack and stroke, and accelerates progression to kidney failure. ADI develops in the early stages of the disease when the patient loses between 20 and 50% of the overall renal function. ADI in patients without dialysis, historically, CKD has been treated with intravenous infusions that accumulate iron grades temporarily to avoid complications of fitness. 40-year-old kidney patient with anemia, I know firsthand.
Unfortunately, Medicare patients with renal anemia have yet to move to outpatient services for intravenous therapy. Like dialysis patients, these patients face increased tension and a threat of viral exposure when they stop at infusion and outpatient centers. For this situation, a sensible step lawmakers can take to ensure that patients can safely treat their renal anemia would be to repair patient selection and access the only FDA-approved oral therapy for IDA rather than intravenous infusion.
Oral therapy, a complex coordination of ferric citrate, is a cutting-edge compound that has been clinically shown to treat iron deficiency anemia well in non-dialysized renal patients. The medicine is oral, allowing patients to remain safe at home and avoid exposure to COVID. Since the FDA approved the oral drug in 2014, iron citrate has been acclaimed through teams of doctors, patients, and kidney advocacy organizations such as the American Association of Kidney Patients as a safe means and to overcome the additional burden of visiting crowded outpatient facilities. Selection of cost-effective remedies for renal anemia.
However, despite the apparent benefits for kidney patients, caregivers, and health professionals, the Centers for Medicare
The good news is that a bipartisan organization of congressional leaders has identified the seriousness of the challenge and has come out to act on behalf of patients with kidney disease. Recently Presented by Representatives Larry BucshonLarry Dean Bucshon Congress to Protect Kidney Failure Patients During the COVID-19 Pandemic NIH begins studying hydroxychloroquine and azithromycin as RAISE (Supporting Renal Anemia Innovation and Expansion). | House adopts spending to win the 5G race | Federal Government Sounds Alarm on Iran’s Cyber Risk | Ivanka Trump’s appearance on the tech screen provokes a backlash MORE (R-Ind. ), Kidney Committee Co-Chair Tom O’Halleran (D-Ariz. ), GK ButterfieldGeorge (GK) Congress Kenneth Butterfield will have to protect to Kidney Failure Patients COVID-19 Pandemic Time for HELP is Now: Senate Expected to Pass Bill to Speed Recovery from Herbal Errors Representative Clyburn on Confederate Statues: Crowd Action is Not an Answer MORE (DN. C. ), and Markwayne Mullin Markwayne Mullin Congress Must Protect Kidney Patients During COVID-19 Pandemic Georgia Strengthens Democracy and Closes NATO with US Help Five Takeaways from PPP PLUS Loan Awareness (R-Okla. ) It would update existing Medicare policy to ensure that thousands of high-risk kidney patients regain their selection for treatment. nt of domestic anemia. This policy replacement will help protect vulnerable patients from COVID-19, decrease the burden on kidney patients and the burden on ambulatory infusion centers.
In a national economic and fitness crisis, there is no single miracle solution that protects all kidney patients who access the care they need, but in the event of a crisis, it is the government’s duty, not patients’ duty, to remove barriers. that the government itself has created and exacerbates the dangers to patients. The Medicare policy of cord citrate, along with other proactive efforts to ensure that patients with renal CKD have access to the care they need, such as telemedicine, is a vital and intelligent step forward.
Conway is president of global policy and affairs for the American Association of Renal Patients (AAKP) and a former leader of the U. S. Department of Labor.
Look at the thread.
The Hill 1625 K Street, NW Suite 900 Washington DC 20006202-628-8500 phone 202-628-8503 fax
The content of this is © 2020 Capitol Hill Publishing Corp. , a subsidiary of News Communications, Inc.